React Health is pleased to announce the appointment of Dr. Colleen G. Lance as its Chief Medical Officer. Dr. Lance is joining React Health as part of its executive leadership team effective November 2, 2023. She most recently was a staff physician at the Cleveland Clinic, serving as Medical Director […]
Industry News
Nox Health: New Directors Bring Significant Experience Across Health Systems, Employer benefits and Care Delivery
Nox Health, a global sleep health leader in sleep diagnostics and value-based sleep care management, today announced the appointment of three new board members: Lloyd Dean, Chief Executive Emeritus, CommonSpirit Health; David Schlanger, Executive Chairman, Progyny; Dr. Bill Lewis, Telehealth Consultant to Fortune 500 companies. “Sleep is the missing gap […]
EnsoData and React Health Partner to Improve Outcomes with Predictive AI
EnsoData, a leading provider of artificial intelligence (AI) solutions to assist with sleep testing, diagnosis, and treatment, and React Health, a sleep and respiratory device manufacturer based in Sarasota, FL, have announced a strategic collaboration to optimize PAP adherence support for patients with sleep apnea. EnsoData’s revolutionary adherence prediction AI […]
Potential Apple Watch Ban Over Masimo Pulse Ox Technology Infringement
Masimo announced that the United States International Trade Commission (USITC) has recommended a limited exclusion order for infringing Apple Watches with light-based pulse oximetry functionality. The USITC found that Apple violated U.S. laws by incorporating Masimo’s patented light-based pulse oximetry technology in its products. The exclusion is scheduled to go […]
HGNS Maker Nyxoah Partners with ResMed Germany
Nyxoah SA today announced that the Company has entered into a partnership with ResMed Germany to increase OSA awareness and therapy penetration in the German market. Nyxoah and ResMed Germany will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment. […]
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
ProSomnus, Inc. has announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus’s Executive Chair, Chief Executive Officer, and Chief Financial Officer are also participating in the financing. A description of the terms of the offering can […]
Nox Health Names Brigitte Nettesheim as President, Enterprise
Nox Health, a global leader in sleep diagnostics and value-based sleep care management, today announced that Brigitte Nettesheim has been appointed President, Nox Health, Enterprise business, effective immediately. In this role, Brigitte will have responsibility for Nox Health’s value-based sleep care management business, which provides plan sponsors and health plans […]
Inspire Medical Systems Reports Strong Growth in Second Quarter
Inspire Medical Systems, Inc. has reported financial results and significant achievements for the quarter ended June 30, 2023. Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems, expressed satisfaction with the company’s performance in the second quarter. He attributed the growth to increased utilization at existing sites […]
Landmark Results from Two Noctrix Health TOMAC RLS Therapy Studies
Noctrix Health, Inc. announced a double feature in the renowned peer-reviewed journal, Sleep, showcasing the outcomes of two major clinical trials that assessed TOMAC therapy for the treatment of restless legs syndrome (RLS). The two papers feature the results from the RESTFUL study (NCT04874155), a multi-center, randomized, sham-controlled clinical trial, and a subsequent […]
ProSomnus to Design Head-to-Head Clinical Trial: OAT vs. Hypoglossal Nerve Stimulation
ProSomnus, Inc. announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HGNS) in treating patients with severe OSA. The clinical trial plans follow updated results from the First Line Obstructive Sleep Apnea Treatment Study (FLOSAT), a prospective, independent, head-to-head, crossover […]













